Bloomberg Sign InSubscribe
Business
Predictive Technology Group Announces Launch of PGxPLUS+™ Pharmacogenomic Test and Reaches Clinical Study Enrollment
August 9, 2019, 9:15 AM EDT
SHARE THIS ARTICLE
Share
Tweet
Post
Email
Predictive Technology Group Announces Launch of PGxPLUS+™ Pharmacogenomic Test
and Reaches Clinical Study Enrollment Milestone
Enrollment reaches 350 patients for IRB-approved study focused on chronic pain
SALT LAKE CITY, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group,
Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease
identification and subsequent clinical intervention through precision
therapies, announces that its wholly owned subsidiary Predictive Laboratories,
Inc. has commercially launched PGxPLUS+, a pharmacogenomic test panel being
marketed to pain clinics for patients with chronic pain. PGxPLUS+ evaluates
genetic factors that play a major role in an individual’s response to
medications. In parallel, Predictive Laboratories has reached a milestone of
enrolling 350 patients with chronic pain into an Investigational Review
Board-approved clinical study aimed at providing additional insight into the
mechanisms of chronic pain and responses to pain therapies.
Predictive Technology Group is tackling chronic pain and the opioid crisis on
multiple fronts. Predictive has already developed and in-licensed important
prognostic DNA tests and novel treatments for osteoarthritis, lumbar disc
disease, endometriosis, and other conditions causing chronic pain. In 2016,
the Institute of Medicine estimated that up to one-third of the U.S.
population lives with ongoing pain. Chronic pain is often triggered by one of
these common conditions, and over time can develop into a chronic pain
syndrome, which is a disease itself.
The PGxPLUS+ panel is one of the most comprehensive pharmacogenetic tests
available on the market. Predictive’s test evaluates 112 genetic variants
across 38 genes that affect the metabolism of over 150 common medications,
including pain medications. More than 90% of the population has one or more
gene variants that affect the efficacy or safety of prescription drugs.
Variation in drug metabolism is largely determined by an individual’s genetic
profile, blood levels of a drug may vary up to 1,000-fold in similar patients
taking identical doses of the same drug. Pharmacogenomics is the study of the
role of our genome in drug responses.
Dr. Bryt Christensen, M.D., a pain specialist, reports, “The PGxPLUS+
pharmacogenetic test has been very helpful in my day-to-day practice. The
results give insights into why some patients are not responding to medications
as expected. With the help of these test results, I have been able to start
or switch medications for patients more successfully. The PGxPLUS+ test helps
me avoid prescribing medications that a patient won’t metabolize well, leading
to better and more personalized patient care.”
One-third of patients taking long-term opioid therapy for non-cancer chronic
pain either find their medication to be ineffective or they do not tolerate
the side effects of the treatment. In the clinical study, Predictive is
testing patients who are taking high doses of opioids [≥50 morphine milligram
equivalents (MME)/day] for genetic variants responsible for their underlying
disease, their metabolism of opioids, their intrinsic pain thresholds, and any
genetic predisposition to opioid addiction. Predictive plans to develop more
comprehensive treatment guidelines for pain based on predictive genetic
markers.
“The ability to effectively treat individuals in pain represents a significant
market opportunity and of even greater importance it serves an obligation of
society to alleviate the current pain and suffering of an individual in a
safer and more effective manner,” said Bradley Robinson, CEO of Predictive
Technology Group. “Our Company is both identifying the most effective ways to
treat pain at a personalized level and working to understand the underlying
cause of diseases like osteoarthritis, lumbar disc disease and endometriosis
to treat or prevent the root cause of the pain. We are pleased to add the
PGxPLUS+ test to our portfolio of regenerative medicine and diagnostic
products focused on treating chronic pain diseases.”
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through
predictive data analytics, novel gene-based diagnostics and companion
therapeutics through its subsidiaries Predictive Therapeutics, Predictive
Biotech, and Predictive Laboratories. These subsidiaries are focused on
endometriosis, scoliosis, degenerative disc disease, and human cell and tissue
products. The subsidiaries use genetic and other information as cornerstones
in the development of new diagnostics that assess a person’s risk of illness
and therapeutic products designed to identify, prevent and treat diseases more
effectively. Additional information is
available at Predtechgroup.com, Predrx.com, Predictivebiotech.com,
and Predictivelabs.com.
